All In Biotech

Drug Trial Radar · NCT07780383

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Jun 17, 2027

Study completion Jun 17, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

Conditions

  • Alzheimer's Disease
  • Healthy Participants

Interventions

  • BMS-986446Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusionTime frame: Up to approximately 5 months
  2. Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusionTime frame: Up to approximately 5 months
  3. Maximum observed concentration (Cmax)Time frame: Up to approximately 5 months
  4. Time of maximum observed concentration (Tmax)Time frame: Up to approximately 5 months
  5. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to approximately 5 months
  6. Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))Time frame: Up to approximately 5 months
  7. AUC(INF)Time frame: Up to approximately 5 months
  8. Half-life (T-HALF)Time frame: Up to approximately 5 months
  9. Apparent total body clearance in SC administration (CLT/F)Time frame: Up to approximately 5 months
  10. Total body clearance in IV infusion (CLT)Time frame: Up to approximately 5 months
  11. Apparent volume of distribution of terminal phase in SC administration (Vz/F)Time frame: Up to approximately 5 months
  12. Volume of distribution of terminal phase (VZ)Time frame: Up to approximately 5 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel ACT (Formerly Anaheim Clinical Trials; LLC)

    Anaheim, California · Recruiting

  • Local Institution - 0003

    Bradenton, Florida · Not yet recruiting

  • Local Institution - 0005

    Daytona Beach, Florida · Not yet recruiting

  • Local Institution - 0007

    Naples, Florida · Not yet recruiting

  • Local Institution - 0006

    The Villages, Florida · Not yet recruiting

  • Local Institution - 0004

    Decatur, Georgia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.